Announcements Trials
Browse Landscape

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 2Melanoma 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Lymphatic Metastasis 1Lung Neoplasms 1Hypoxia 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Disease 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 30Radiotherapy 24pembrolizumab 21Cetuximab 21Docetaxel 13Fluorouracil 12Radiotherapy, Intensity-Modulated 10Paclitaxel 9Radiation 8Nivolumab 7Everolimus 7Carboplatin 7Oxaliplatin 6Gemcitabine 5Surgical Procedures, Operative 4Radiosurgery 4Magnetic Resonance Spectroscopy 4Gefitinib 4Erlotinib Hydrochloride 4Amifostine 4Pemetrexed 3Filgrastim 3Capecitabine 3Bleomycin 3Biopsy 3zalutumumab 2spartalizumab 2pegfilgrastim 2niraparib 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Head and Neck Neoplasms × alovudine × Clear all
NCT00159978 2015-05-07

Validation of 18F-MISO-PET and 18F-FLT-PET

Radboud University Medical Center

Terminated
21 enrolled
Head & Neck

Hypoxia, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡